Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: George Dvorsky who wrote (1645)	9/30/1999 10:33:00 PM
From: Herc	Respond to of 2173

I'm an ophthalmologist and, as I said earlier in the thread, this is huge, huge market. I would say about 1/3 to 1/2 of all obese senior citizens in the U.S. are diabetic. And there are lots of obese senior citizens. There are so many that some days I get grossed out at seeing them all. They never lose weight! This is way more common than cancer, and most of the other biotechs are researching cancer drugs. Diabetes kills lots of folks also. And good control of glucose levels decreases the incidence of diabetes' vascular effects, which is what kills people. Though I generally avoid small biotechs since they are such crapshoots (their one drug fails Stage II or III, and the stock drops 50% in a day, I make take the plunge on AMLN, after a little more DD. Good luck to all!